Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia

Last updated: June 9, 2025
Sponsor: Shanghai Zhongshan Hospital
Overall Status: Active - Recruiting

Phase

1

Condition

Alopecia

Hair Loss

Treatment

Oral DHA + Topical minoxidil 5%

Topical Minoxidil 5%

Clinical Study ID

NCT07012486
B2025-112R
  • Ages 18-40
  • Female

Study Summary

The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is:

• Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA.

Participants will:

  • Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months.

  • Visit the clinic once every month for checkups and tests.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Clinically diagnosed with androgenetic alopecia (AGA)

  • No pregnancy plans within the next 6 months

Exclusion

Exclusion Criteria:

  • Patients who received systemic medications for hair loss within the past 2 months

  • Use of topical medication for hair loss within the past 2 weeks

  • Pregnancy or lactation

  • Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) ormalignancies.

Study Design

Total Participants: 30
Treatment Group(s): 2
Primary Treatment: Oral DHA + Topical minoxidil 5%
Phase: 1
Study Start date:
June 01, 2025
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai 200032
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.